Does Ozempic Cause Muscle Loss? What the STEP-1 Trial Shows

This article is for research and educational purposes only. Not medical advice.

The Muscle Loss Narrative

Since semaglutide (Ozempic, Wegovy) became a household name, a persistent concern has circulated in media coverage and online health communities: that GLP-1 receptor agonists cause disproportionate muscle loss alongside fat loss. The claim is often stated with confidence, but the underlying clinical data tells a more nuanced story.

This article examines the STEP-1 trial — the landmark Phase III study that established semaglutide's efficacy in obesity treatment — and specifically what it found about changes in lean and fat mass.

What the STEP-1 Trial Actually Found

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) randomised 1,961 adults with a BMI ≥30 (or ≥27 with weight-related complications) to receive either subcutaneous semaglutide 2.4 mg weekly or placebo over 68 weeks. The primary endpoint was percentage change in body weight.

Key weight loss results:

• Semaglutide group: mean weight reduction of 14.9% (approximately 15.3 kg)
• Placebo group: mean weight reduction of 2.4%

Of that 14.9% total body weight loss, the trial measured body composition changes using dual-energy X-ray absorptiometry (DEXA) in a subset of participants. Findings showed:

• Fat mass accounted for approximately 65–72% of total weight lost
• Lean mass loss was proportional to the degree of total weight lost, not disproportionate

This is the crucial point. When people lose weight by any means — dietary restriction, bariatric surgery, lifestyle intervention — lean mass loss occurs alongside fat mass loss. The relevant question is not whether lean mass was lost, but whether the proportion lost was greater than expected for the degree of weight reduction. The STEP-1 data did not indicate disproportionate lean mass loss.

The full trial is available on PubMed: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.

Context: How Does It Compare to Other Weight Loss Methods?

Lean mass loss during caloric restriction is well-documented in obesity research. Studies on very-low-calorie diets typically show lean mass comprising 25–35% of total weight lost — a range consistent with what was observed in STEP-1.

For comparison, bariatric surgery (Roux-en-Y gastric bypass) studies show lean mass loss ranging from 20–40% of total weight lost, depending on baseline muscle mass, protein intake, and exercise habits. The semaglutide data falls within a similar range.

This comparison is important: GLP-1 agonists are not uniquely catabolic. The lean mass loss observed is a consequence of significant weight reduction rather than a specific pharmacological effect on muscle tissue.

Resistance Training as a Mitigating Factor

Where the media narrative has a partial basis in reality is in the absence of resistance training. Studies across all weight loss interventions consistently show that progressive resistance training significantly attenuates lean mass loss. Participants in STEP-1 were not enrolled in structured exercise programmes — they received standard lifestyle counselling.

For someone undergoing semaglutide treatment who wants to preserve muscle mass, the evidence strongly supports combining GLP-1 therapy with resistance training and adequate dietary protein (≥1.2 g/kg body weight/day) — the specifics of how protein intake supports weight loss and muscle retention are covered in detail separately. This is not a concern specific to semaglutide — it applies to all forms of significant weight loss.

What About Next-Generation Agents?

The question of lean mass preservation becomes more relevant when considering compounds under investigation that may produce even greater absolute weight loss. Researchers studying retatrutide — the triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — have noted particular interest in whether its unique mechanism might influence lean mass outcomes differently at the higher levels of weight reduction it produces.

Some preclinical data suggests GIP receptor activation may have direct effects on muscle metabolism, though human trial data on lean mass composition with tirzepatide and retatrutide is still emerging. This is one of several reasons why the retatrutide 20 mg from RetaLABS has become a reference for Australian researchers tracking triple agonist peptides.

The Protein Synthesis Question

There is a separate mechanistic question about whether GLP-1 receptor activation has any direct effect on muscle protein synthesis. Some rodent studies have suggested GLP-1 receptors may be expressed on skeletal muscle, but the relevance to human physiology at therapeutic doses is unclear. This area remains under investigation and is not established clinical science.

Practical Implications for Research

For researchers and clinicians tracking the GLP-1 agonist landscape in Australia, the muscle loss question is worth monitoring closely as Phase III data for newer compounds matures. The STEP-1 data provides a useful benchmark: lean mass loss with semaglutide is proportional, not disproportionate, and consistent with other weight loss interventions of similar magnitude.

Understanding how GLP-1 agonists work mechanistically provides important context for interpreting these body composition findings.

Summary

The STEP-1 trial data does not support the media narrative that semaglutide causes disproportionate muscle loss. For a comprehensive overview of Ozempic in Australia — including PBS cost, access pathways, supply status, and side effect guidance — see the Ozempic Australia 2026 cost and access guide. Lean mass loss during GLP-1 agonist treatment is consistent with what is observed across other significant weight loss interventions. The appropriate response — as with any weight loss intervention — is adequate protein intake and resistance training, not avoidance of the therapy based on overstated muscle loss concerns. As next-generation agents with greater weight loss efficacy advance through trials, monitoring lean mass outcomes will be an increasingly important secondary endpoint.